These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12483068)

  • 1. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients.
    Chicella M; Jansen P; Parthiban A; Marlowe KF; Bencsath FA; Krueger KP; Boerth R
    Crit Care Med; 2002 Dec; 30(12):2752-6. PubMed ID: 12483068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation.
    Barnes BJ; Gerst C; Smith JR; Terrell AR; Mullins ME
    Pharmacotherapy; 2006 Jan; 26(1):23-33. PubMed ID: 16422667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of continuous infusion lorazepam to serum propylene glycol concentration in critically ill adults.
    Arroliga AC; Shehab N; McCarthy K; Gonzales JP
    Crit Care Med; 2004 Aug; 32(8):1709-14. PubMed ID: 15286548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propylene glycol accumulation in critically ill patients receiving continuous intravenous lorazepam infusions.
    Horinek EL; Kiser TH; Fish DN; MacLaren R
    Ann Pharmacother; 2009 Dec; 43(12):1964-71. PubMed ID: 19920159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propylene glycol-associated renal toxicity from lorazepam infusion.
    Yaucher NE; Fish JT; Smith HW; Wells JA
    Pharmacotherapy; 2003 Sep; 23(9):1094-9. PubMed ID: 14524641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity.
    Yahwak JA; Riker RR; Fraser GL; Subak-Sharpe S
    Pharmacotherapy; 2008 Aug; 28(8):984-91. PubMed ID: 18657015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients.
    Nelsen JL; Haas CE; Habtemariam B; Kaufman DC; Partridge A; Welle S; Forrest A
    J Intensive Care Med; 2008; 23(3):184-94. PubMed ID: 18543419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propylene glycol-induced lactic acidosis in a patient with normal renal function: a proposed mechanism and monitoring recommendations.
    Neale BW; Mesler EL; Young M; Rebuck JA; Weise WJ
    Ann Pharmacother; 2005 Oct; 39(10):1732-6. PubMed ID: 16159998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion.
    Reynolds HN; Teiken P; Regan ME; Habashi NM; Cottingham C; McCunn M; Scalea TM
    Crit Care Med; 2000 May; 28(5):1631-4. PubMed ID: 10834725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy.
    Parker MG; Fraser GL; Watson DM; Riker RR
    Intensive Care Med; 2002 Jan; 28(1):81-4. PubMed ID: 11819005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Evaluation of a Guideline for Monitoring Propylene Glycol Toxicity in Pediatric Intensive Care Unit Patients Receiving Continuous Infusion Lorazepam.
    Hansen L; Lange R; Gupta S
    J Pediatr Pharmacol Ther; 2015; 20(5):367-72. PubMed ID: 26472950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propylene glycol accumulation after high-dose lorazepam: what have we learned?
    Bouchard NC; Fulton JA; Hoffman RS
    Crit Care Med; 2005 Feb; 33(2):468; author reply 468. PubMed ID: 15699876
    [No Abstract]   [Full Text] [Related]  

  • 13. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.
    Wilson KC; Reardon C; Theodore AC; Farber HW
    Chest; 2005 Sep; 128(3):1674-81. PubMed ID: 16162774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients.
    Wilson KC; Farber HW
    J Intensive Care Med; 2008; 23(6):413; author reply 414-5. PubMed ID: 19019841
    [No Abstract]   [Full Text] [Related]  

  • 15. Medication vehicle injury--using the proper restraint?
    Jacobi J
    Crit Care Med; 2004 Aug; 32(8):1800-1. PubMed ID: 15286569
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe lactic acidosis after an iatrogenic propylene glycol overdose.
    Zosel A; Egelhoff E; Heard K
    Pharmacotherapy; 2010 Feb; 30(2):219. PubMed ID: 20099997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion.
    Greenblatt DJ; von Moltke LL; Ehrenberg BL; Harmatz JS; Corbett KE; Wallace DW; Shader RI
    Crit Care Med; 2000 Aug; 28(8):2750-7. PubMed ID: 10966246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Withdrawal from lorazepam in critically ill children.
    Dominguez KD; Crowley MR; Coleman DM; Katz RW; Wilkins DG; Kelly HW
    Ann Pharmacother; 2006 Jun; 40(6):1035-9. PubMed ID: 16720707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propylene glycol toxicity occurs during low-dose infusions of lorazepam.
    Arbour R
    Crit Care Med; 2003 Feb; 31(2):664-5; author reply 665. PubMed ID: 12576996
    [No Abstract]   [Full Text] [Related]  

  • 20. Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion.
    Arbour RB
    Am J Crit Care; 1999 Jan; 8(1):499-506. PubMed ID: 9987548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.